会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • CONTROL DEVICE FOR TRANSMITTING AN ITEM OF CONTROL INFORMATION TO A LAMP UNIT AND METHOD
    • 控制装置控制信息在灯单元和方法传输
    • WO2011104060A3
    • 2012-02-09
    • PCT/EP2011051054
    • 2011-01-26
    • INSTA ELEKTRO GMBHKRAUSE KARL-HEINZ
    • KRAUSE KARL-HEINZ
    • H05B37/02H02J13/00H04B3/54
    • H05B37/0263H02J13/002H04B3/54H04B2203/5412
    • A control device (1) for transmitting an item of control information to at least one lamp unit, which has at least one light-emitting means and can be operated on alternating current, has a switchable output stage (18), a power supply (20), a zero crossing identification device (13) and a modulator for generating a modulation voltage for applying the item of control information to the AC voltage supplied to the lamp unit via the control device (1). Part of the control device (1) is also a logic unit (14). The control device (1) has a switchable parallel branch (21), via which, when switched, an impedance can be connected which is greater than the impedance of the output stage (18). In this case, provision is made for the parallel branch (21), when switched, to form a shunt via the power supply (20) in such a way that the internal resistance of the power supply (20) or, in the event of the presence of a plurality of internal resistances in the power supply (20), said internal resistances represent, overall or partially, the usable impedance. The invention also describes a method for determining the time of the beginning of a modulation phase following an operating phase by means of a control device (1), with a shunt being switched once said operating phase has ended in the lamp unit. Prior to the beginning of the shunt circuit flow connected on the lamp side, the output stage (18) is deactivated and the parallel branch (21) is activated in the control device (1). Upon detection of the shunt circuit flow, the output stage (18) is then activated and the parallel branch (21) deactivated before the data transmission begins.
    • 用于发送控制信息给至少一个的至少一个光源具有,AC可操作灯单元上的控制装置(1)有一个可切换输出级(18),电源(20),过零个检测装置(13),以及用于产生调制电压施加到调制器 通过控制单元将所述控制信息提供给灯单元(1)供给的交流电压。 所述控制单元(1)的部分还包括一个逻辑单元(14)。 的控制装置(1)具有可切换的并联支路(21),通过该连接时,阻抗可以被切换,这比所述输出级(18)的阻抗越大。 它提供的是,并联支路(21)连接时,跨接在电源分流(20),使得所述电源(20)中或多个内部电阻的存在在电源(20),这些全部或部分的内部电阻,有用 代表阻抗。 中进一步描述用于由控制装置(1),其在分流灯单元的操作相结束后切换的手段确定在相位调制的随后的操作阶段的开始的定时的方法。 在所述控制单元(1)的灯侧连接的次级电流流动开始之前,输出级(18)被禁用和并行分支(21)被激活。 与检测次级电流的,输出级(18)然后被活化和数据传送开始前的并联支路(21)被禁用。
    • 2. 发明申请
    • SELECTION OF STEM CELL CLONES WITH DEFINED DIFFERENTIATION CAPABILITIES
    • 具有确定的分化能力的干细胞克隆的选择
    • WO2011068879A3
    • 2011-11-17
    • PCT/US2010058570
    • 2010-12-01
    • RES DEV FOUNDATIONPREYNAT-SEAUVE OLIVIERKRAUSE KARL-HEINZ
    • PREYNAT-SEAUVE OLIVIERKRAUSE KARL-HEINZ
    • C12N5/0735A61K35/12C12N5/077C12N5/079
    • C12N5/0606C12N2503/02G01N33/5014G01N33/5044
    • Disclosed are methods for producing a clonal population of cells involving: a) obtaining a population of pluripotent or multipotent cells that have been expanded in vitro and maintained in an undifferentiated or essentially undifferentiated state; b) expanding individualized cells of the population into clonal populations of cells; and c) selecting one or more clonal population of cells determined to have the ability to differentiate into a population that is at least about 50% homogeneous for either neural cell types, hepatocytes, or cardiomyocytes. Also disclosed are clonal populations of cells produced by the methods of the present invention, and methods of treating disease in subjects involving administration of clonal cells of the present invention to a subject. Methods of screening test compounds that involve contacting a test compound with a clonal population of cells produced by the methods of the present invention are also set forth.
    • 公开了产生克隆细胞群体的方法,包括:a)获得体外扩增并维持未分化或基本未分化状态的多能或多能细胞群体; b)将该群体的个体化细胞扩增为克隆细胞群体; 和c)选择一个或多个被确定为具有分化为对于神经细胞类型,肝细胞或心肌细胞至少约50%同质的群体的能力的克隆细胞群体。 还公开了通过本发明的方法产生的细胞的克隆群体,以及在涉及将本发明的克隆细胞给予受试者的受试者中治疗疾病的方法。 筛选包括使测试化合物与通过本发明的方法产生的克隆细胞群接触的测试化合物的方法。
    • 5. 发明申请
    • NOVEL MEANS AND METHODS FOR THE TREATMENT OF HEARING LOSS AND PHANTOM HEARING
    • 治疗听力损失和听觉听觉的新手段和方法
    • WO2005119251A2
    • 2005-12-15
    • PCT/EP2005/006061
    • 2005-06-06
    • UNIVERSITY OF GENEVAKRAUSE, Karl-HeinzBANFI, Botond
    • KRAUSE, Karl-HeinzBANFI, Botond
    • G01N33/50
    • C12N15/1137A61K31/713A61K45/06A61K49/0008C12N2310/11C12N2320/31G01N33/5088G01N2333/90209G01N2800/14
    • This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test compound binds to said protein or, if present, said subunit(s); and (c) determining whether (ca) said test compound, upon contacting in step (a); or (cb) said test compound, upon binding in step (b) modulates the expression and/or activity of said protein or, if present, said subunit(s). Also provided are pharmaceutical compositions, medical uses and diagnostic uses of compounds of the invention.
    • 本发明涉及一种鉴定NADPH氧化酶调节剂的方法,其中所述调节剂适合作为用于治疗和/或预防听力损失和/或幻影听觉的铅化合物和/或药物,该方法包括 (a)使测试化合物与蛋白质接触的步骤,其中所述蛋白质(i)包含SEQ ID NO:1,3或5中任一个的氨基酸序列或由其组成,或(ii)由核酸编码 包含SEQ ID NO:2,4,6,23或24中任一项的序列或由其组成的酸,或(iii)是根据(i)或(ii)的蛋白质的片段,并且表现出NADPH氧化酶活性, 或(iv)具有与根据(i)或(ii)的蛋白质或根据(iii)的片段至少75%相同的序列并显示NADPH氧化酶活性的序列,并且任选地含有一个或多个NADPH氧化酶亚基, 允许所述测试化合物结合所述蛋白质或如果存在的话,所述亚基的条件; (b)任选地确定所述测试化合物是否结合所述蛋白质,或者如果存在,则是所述亚基; 和(c)在步骤(a)中确定(ca)所述测试化合物在接触时是否存在。 或(cb)所述测试化合物在步骤(b)中结合时调节所述蛋白质的表达和/或活性,或如果存在,则调节所述亚基。 还提供了本发明化合物的药物组合物,医疗用途和诊断用途。
    • 6. 发明申请
    • VERFAHREN ZUR PERMANENTEN REDUNDANTEN ÜBERTRAGUNG VON DATENTELEGRAMMEN IN KOMMUNIKATIONSSYSTEMEN
    • 方法为数据报文通信系统永久冗余传输
    • WO2004030284A1
    • 2004-04-08
    • PCT/DE2003/002958
    • 2003-09-05
    • SIEMENS AKTIENGESELLSCHAFTBRÜCKNER, DieterKLOTZ, DieterKRAUSE, Karl-Heinz
    • BRÜCKNER, DieterKLOTZ, DieterKRAUSE, Karl-Heinz
    • H04L12/56
    • H04L12/462H04L45/00H04L45/24H04L45/28H04L45/66
    • Mit dem erfindungsgemäßen Verfahren ist eine permanente redundante Übertragung von Datentelegrammen auf disjunkten Pfaden möglich, wobei zirkulierende Datentelegramme zuverlässig erkannt und vernichtet werden können. Darüber hinaus erfolgt die Aufspaltung auf zwei Datentelegramme an der entsprechenden Verzweigungsstelle transparent, und es entsteht beim Empfänger keine zusätzliche Belastung durch den Empfang zweier identischer Datentelegramme, beispielsweise durch die Zuordnung einer aktuellen Zyklusnummer zu den empfangenen Datentelegrammen in einem zyklischen Kommunikationssystem (26). In einem nicht zyklischen Kommunikationssystem kann dies durch softwaretechnische Behandlung, beispielsweise der Headerkennung der Datentelegramme, ebenfalls gewährleistet werden. Insbesondere wird darüber hinaus das Verhalten des Kommunikationssystems (26) hinsichtlich "Lernen" von Adressen in den einzelnen Teilnehmern (1, 2, 3, 4, 5), insbesondere den Switches, für den gesamten übrigen, nicht redundanten Datenverkehr nicht verändert.
    • 利用本发明的方法的数据消息的对不相交路径的永久冗余传输是可能的,循环的数据报文可以可靠地检测和破坏。 此外,两个数据帧到对应的分支点处的分裂是透明的,并且通过接收两个相同的数据报文的接收器处则产生没有额外的负载,例如,由电流周期数目,以环状的通信系统(26)接收到的数据消息的分配。 在一个非周期的通信系统中,这还可以通过软件技术处理保证,如头部检测的数据报文的。 具体地,此外,所述通信系统(26)相对于的行为“学习”中各个站(1,2,3,4,5),尤其是开关,不改变整个剩余的非冗余数据业务地址。
    • 10. 发明申请
    • MATERIAL FOR PRODUCING PRODUCTS HAVING FIBRINOLYTIC AND/OR ANTIBACTERIAL PROPERTIES
    • 材料对产品的纤维蛋白溶解和/或抗菌特性上的制造
    • WO0230388A3
    • 2003-01-09
    • PCT/DE0103587
    • 2001-09-19
    • INTECH THUERINGEN GMBHSCHUNK WERNERBRUDER MICHAELGIESSMANN KONRADKRAUSE KARL-HEINZMERKMANN GERHARD
    • SCHUNK WERNERBRUDER MICHAELGIESSMANN KONRADKRAUSE KARL-HEINZMERKMANN GERHARD
    • A61K9/00A61K9/14A61M1/14A01N25/00B01D53/02B01D71/00B01J20/20
    • A61K9/0024A61K9/143
    • The invention relates to a material for producing products (1) having fibrinolytic and/or antibacterial properties. Said material has at least one matrix (2), which is compatible with body tissue and in which a molecular sieve is incorporated. Said molecular sieve is loaded with: at least one active substance (Z) having a fibrinolytic or antibacterial effect; or at least one first active substance (Z1) having a fibrinolytic effect and a second active substance (Z2) having an antibacterial effect. The corresponding molecular sieve/active substance adduct (3) releases the active substance(s) in conjunction with the aqueous body fluid when the matrix (2) is in contact with the body tissue (4). The inventive material is characterized in that the molecular sieve/active substance adduct (3) additionally contains water of crystallization to such an extent that the molecular sieve is partially dehydrated with regard to a sufficient basic molar quantity (m) of water of crystallization. The molecular sieve is loaded with the reduced molar quantity (m') of water of crystallization with the active substance(s) (Z, Z1, Z2) so that an adsorption of water with the desorption of the corresponding active substance occurs when the matrix (2) is in contact with the body tissue (4), whereby the water of crystallization of the molecular sieve increases. The invention also relates to an advantageous method for producing the inventive active substance.
    • 本发明涉及一种材料,所生产的产品(1)纤维蛋白溶解和/或抗菌性能,其包括至少一个身体组织相容性基质(2)到其中的分子筛是混合的,所述至少一种活性物质(Z)与血纤维蛋白溶解或抗菌作用或 至少一种第一活性成分(Z1),其具有纤维蛋白溶解活性和第二剂(Z2)装载有抗菌作用,其中相应的分子筛/活性物质在与身体组织(4)结合基质(2)的接触加合物(3) 水性体液/释放药物/秒。 本发明的材料现在的特征在于,所述分子筛/活性物质的加合物(3)还含有结晶水,并使得相对于结晶水的足够碱性的摩尔量(M),所述分子筛是部分脱水的方法,其中所述分子筛包含 减少摩尔量(M“)被加载在结晶水与/活性成分/ s的(Z,Z1,Z2),这样,在由相应的活性成分staffindet解吸的矩阵(2)与身体组织(4)的水吸附的接触 其中的分子筛增加结晶水含量。 此外,提出了一种用于生产本发明材料的有利方法。